Azenta, Inc. (NASDAQ:AZTA) Sees Significant Decrease in Short Interest

Azenta, Inc. (NASDAQ:AZTA) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 4,340,000 shares, a decline of 9.8% from the October 15th total of 4,810,000 shares. Currently, 9.1% of the shares of the company are short sold. Based on an average trading volume of 552,300 shares, the short-interest ratio is currently 7.9 days.

Insider Transactions at Azenta

In other news, CFO Herman Cueto sold 1,595 shares of the business’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total value of $69,669.60. Following the completion of the sale, the chief financial officer now owns 24,604 shares of the company’s stock, valued at approximately $1,074,702.72. The trade was a 6.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.77% of the company’s stock.

Institutional Trading of Azenta

Several large investors have recently bought and sold shares of the business. Hantz Financial Services Inc. bought a new position in shares of Azenta in the second quarter worth about $30,000. Farther Finance Advisors LLC lifted its stake in Azenta by 20.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after purchasing an additional 256 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Azenta by 150.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after purchasing an additional 955 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Azenta in the first quarter valued at approximately $130,000. Finally, Acadian Asset Management LLC grew its stake in shares of Azenta by 24.7% during the first quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after buying an additional 471 shares during the last quarter. 99.08% of the stock is owned by institutional investors and hedge funds.

Azenta Stock Performance

Shares of NASDAQ:AZTA opened at $40.37 on Tuesday. The firm has a 50 day moving average of $45.44 and a 200-day moving average of $50.35. Azenta has a 12 month low of $38.82 and a 12 month high of $69.16.

Azenta (NASDAQ:AZTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.10 by $0.08. The business had revenue of $170.00 million during the quarter, compared to the consensus estimate of $169.66 million. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The company’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 earnings per share. As a group, equities research analysts predict that Azenta will post 0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZTA has been the topic of a number of analyst reports. Evercore ISI decreased their target price on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC reduced their price target on Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Azenta currently has an average rating of “Hold” and an average target price of $63.60.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.